Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
April 24, 2023 11:16 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, April 24, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...
Mydecine Innovations Group Provides Corporate Update
April 03, 2023 06:00 ET
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...
Mydecine Reports Financial Results for the Year Ended December 2022
March 31, 2023 20:21 ET
|
Mydecine Innovations Group Inc.
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of...
Mydecine Announces Debt Settlements
March 06, 2023 07:00 ET
|
Mydecine Innovations Group Inc.
DENVER, March 06, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
December 12, 2022 11:39 ET
|
Mydecine Innovations Group Inc.
DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
November 21, 2022 12:01 ET
|
Mydecine Innovations Group Inc.
DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
November 14, 2022 17:44 ET
|
Mydecine Innovations Group Inc.
DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of...
Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.
September 01, 2022 10:00 ET
|
Mydecine Innovations Group Inc.
DENVER, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of...
Mydecine Innovations Group Announces Common Share Subscription Agreement
August 29, 2022 16:00 ET
|
Mydecine Innovations Group Inc.
DENVER, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of...
Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
August 19, 2022 11:06 ET
|
Mydecine Innovations Group Inc.
DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of...